ADIAL PHARMACEUTICALS INC (ADIL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.12+6.91%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ADIL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on advancing AT177, a colon-targeted AhR agonist, through IND filing and Phase 1 clinical trials in 2027 for ulcerative colitis treatment.
Stated as a priority in 2 quarters including 2026-Q2 and a June 2026 press release. The company completed acquisition of Azora and raised $32 million upfront, increasing cash from $4.6M in 2026-Q1 to $28.7M in 2026-Q2 to fund AT177 development. Management plans IND filing in first half 2027 and Phase 1 trials in second half 2027, delivering on stated clinical advancement milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Focus is now on advancing AT177 into the clinic in 2027.”
Progress AD04, a genetically targeted treatment for Alcohol Use Disorder, toward Phase 3 clinical trials and regulatory approval pathways.
Stated in 2 quarters including 2026-Q1 and 2025-Q4. AD04 development is progressing with regulatory momentum and strategic partnerships. Cash was $4.6M in 2026-Q1, supporting operations. Net loss was $2.0M in 2026-Q1. The trajectory shows continued progress toward late-stage development and regulatory clarity.
“Continued progress to advance AD04 toward late-stage development and regulatory progress.”
“Regulatory and strategic developments position AD04 for late-stage development.”
Build a commercial pathway for AD04 in Europe through a collaboration framework agreement with Molteni Farmaceutici.
Stated in 2 quarters including 2026-Q1 and 2025-Q4. Management has emphasized the strategic partnership framework with Molteni Farmaceutici to commercialize AD04 in Europe. No specific financial milestones disclosed yet. The priority remains active with ongoing partnership development.
“Established collaboration framework with Molteni Farmaceutici for AD04 commercialization in Europe.”
“Building commercial pathway for AD04 in Europe with Molteni Farmaceutici.”
Maintain financial discipline including managing capital allocation, financing, and stockholder equity to support operations and growth.
Stated in 3 quarters including 2026-Q1 and 2026-Q2. The company raised $32 million upfront in 2026-Q2, increasing cash from $4.6M to $28.7M, supporting operations into late 2027. However, stockholders' deficit was ($38.4M) at 2026-Q2 and Nasdaq issued a notice for not meeting equity requirements. Management is actively managing capital allocation amid financial challenges, showing mixed progress.
“Closed initial $32 million tranche of private placement to strengthen financial position.”
“Received Nasdaq notice for not satisfying minimum stockholders' equity requirement.”
“Existing cash and cash equivalents will fund operating expenses into second half of 2026.”
Enhance patent protection and intellectual property rights for AD04 to support long-term platform value.
Stated in 2 quarters including 2026-Q1 and 2025-Q4. Management highlights publication of international patent application extending AD04 protection through at least 2045. No financial impact disclosed yet. The priority remains a continuing focus to support platform value.
“Strengthened intellectual property position including publication of international patent application for AD04.”
“IP advancements reinforce long-term value of AD04 platform.”
Over the trailing year it converted 0.48x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
31 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.